Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC

This is an open-label, multi-center 2A study evaluating the safety and efficacy of 177Lu-TLX250, a CAIX-targeting radioligand therapy, in adult participants with advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC).

The objective is to determine the recommended Phase 3 dose (RP3D) for use in Phase 3 study.

• 177Lu-TLX250 (Drug), also known as TLX250-Tx, 177Lu girentuximab tetraxetan: 3 infusions of 177Lu-TLX250 at 8-week intervals or 6 infusions 177Lu-TLX250 at 4-week intervals

Primary outcomes

• Dose Optimization -safety and tolerability [Through study completion, an average of 1.5 years]: Assessing adverse events of special interest (AESIs), incidence and severity of treatment-emergent adverse events (TEAEs) and frequency, severity according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V5.0, seriousness, and relationship of study treatment will be assessed. Laboratory abnormalities will be assessed according to the NCI CTCAE V5.0.

Secondary outcomes

• Evaluate blood radioactive PK parameter- Cmax (maximum plasma concentration) [Treatment period (4 months)]: Gamma-counting blood radioactivity will be used to derive this pharmacokinetics parameter
• Evaluate blood radioactive PK parameter- AUCinf (area under blood concentration time curve from zero to infinity) [During Treatment (4 months)]: Gamma-counting blood radioactivity will be used to derive this pharmacokinetics parameter.
• Evaluate blood radioactive PK parameter- t1/2 (Terminal half-life) [During Treatment (4 months)]: Gamma-counting blood radioactivity will be used to derive this pharmacokinetics parameter.
• Evaluate blood radioactive PK parameter- CL (Clearance) [During Treatment (4 months)]: Gamma-counting blood radioactivity will be used to derive this pharmacokinetics parameter.
• Tumor and Organ-specific 177Lu-TLX250 absorbed radiation values [During Treatment (4 months)]: Images-radiation values for tumor and lesions will be measured and analyzed after first and second administration of 177Lu-TLX250.
• TAC for tumor and organ [During Treatment (4 months)]: Time Activity Curves (TAC) will be used to derive time integrated activity parameters in tumor and organ
• Tumor- and organ-specific 177Lu-TLX250 residence time [During Treatment (4 months)]: Residence time of 177Lu-TLX250 in tumor and organs will be derived and interpreted
• Identification of dose-limiting organ(s) [During Treatment (4 months)]: Absorbed dose will be compared to maximal dosimetry threshold for each organ to evaluated the dose limiting organ
• Evaluation of Immunogenicity (anti-drug antibody) [Through study completion, an average of 2 years Outcome Measure]: Incidence of HACA and nAB positivity, overall per treatment group, and per visit (to track incidence over time)
• Monitoring OS (Overall Survival) [Through study completion, an average of 2 years]: Time from the date of randomization to death from any cause
• Monitoring ORR (Objective Response Rate) [Through study completion, an average of 2 years]: Proportion of participants achieving confirmed objective response rate (ORR), i.e., complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) as assessed by a blinded independent central review (BICR)
• Monitoring DoR (Duration of Response) [Through study completion, an average of 2 years]: Time from the first documentation of objective response, i.e., complete response (CR) or partial response (PR) to the first documentation of disease progression or death due to any cause as assessed by blinded independent central review (BICR)
• Monitoring DCR (Disease control Rate) [Through study completion, an average of 2 years]: The proportion of participants achieving confirmed objective response, i.e., complete response (CR), partial response (PR), or stable disease (SD) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR)
• Efficacy- median mPFS [Through study completion, an average of 2 years]: Monitoring disease progression according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* be aged ≥ 18 years.
* have provided written informed consent, dated and signed by the participant prior to any study-specific procedure;
* have relapsed or recurrent, locally advanced, or metastatic RCC with histologically or cytologically confirmed diagnosis of RCC with clear cell component per American Joint Committee on Cancer Staging Manual (Edge SB et al., 2017), with or without sarcomatoid features;
* have received at least 2 and no more than 3 prior lines of systemic therapies for locally advanced or metastatic ccRCC including a PD-1/PD-L1 inhibitor (at least 2 administrations) and a VEGF/VEGFR-targeting agent (including TKI or mAb) in sequence or in combination;
* have had radiographic disease progression occurring during or after the most recent line of therapy or intolerance to most recent line of therapy;
* have at least one measurable lesion according to RECIST, version 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions;
* be CAIX-positive at Screening defined as having at least 1 lesion with a tumor-lesion CAIX ratio of the maximum standardized uptake value (SUVmax) to liver mean standardized uptake value SUVmean) ≥ 1.5 as determined by BICR of 89Zr-TLX250 PET outcomes;
* have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1;
* have recovered from the AEs related to prior lines of therapy or returned to baseline with the exception of Grade 2 neurotoxicity. Ongoing, controlled AEs, such as hypothyroidism or hypertension, are permitted;
* have adequate organ function, defined as:
* Bone Marrow:

  * leukocytes ≥ 3,000/µL;
  * absolute neutrophil count ≥ 1500/µL (administration of granulocyte colony stimulating factor is not allowed within 4 weeks prior to the first administration of 177Lu-TLX250;
  * platelets ≥ 100,000/µL (platelet transfusion is not allowed within 4 weeks prior to the first administration of 177Lu-TLX250); and
  * hemoglobin ≥ 9g/dL (red blood cell transfusion is not allowed within 2 weeks prior to the first administration of 177Lu-TLX250).
* Liver Function:

  * total bilirubin ≤ 1.5 × the upper limit of normal (ULN). For patients with known Gilbert's Syndrome ≤ 3 × ULN is permitted; and
  * alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN or ≤ 5.0 × ULN for participants with liver metastases.
* Renal Function:

  * creatinine clearance ≥ 40 mL/min as measured by Cockroft-Gault formula or directly calculated by 24h urine;
  * have negative pregnancy test for women of childbearing potential (serum); and
* Females of childbearing potential must have a negative serum pregnancy test during screening and prior to the dose of the IMP; must not be breast-feeding; and must agree to use a highly effective method of contraception (see Appendix 10.4) during treatment and for 6 months following last dose of the IMP

Exclusion Criteria:

* have any of the following:

  * visceral metastatic lesions that are ≥ 1 cm that have a CAIX TLR < 1;
  * lytic bone metastatic lesions with a soft tissue component of at least 1 cm with a TLR < 1; and/or
  * at least one metastatic lymph node lesion with short axis ≥ 2.5 cm with a TLR <1;
* received prior 177Lu-TLX250 therapy, any other radioligand therapy, or any prior CAIX-targeting therapy;
* have any known hypersensitivity to compounds of similar chemical or biologic composition to girentuximab, desferrioxamine (DFO) or 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) linker, zirconium or lutetium, and/or any excipient in the study drug or radiographic contrast-agents;
* has received granulocyte colony stimulating factor (G-CSF) or erythropoietin within 4 weeks prior to laboratory evaluations at Screening;
* be currently receiving or have received:

  * any radionuclide within 10 half-lives of the radionuclide prior to 89Zr-TLX250 administration;
  * any type of systemic anticancer therapy within 2 weeks before the first administration of 177Lu-TLX250;
  * prior radiotherapy within 2 weeks prior to the first administration of 177Lu-TLX250 (must have recovered from all radiation-related toxicities and not currently require steroid treatment); and/or
  * prior palliative radiation (≤2 weeks of radiotherapy) within 1-week of the first administration of 177Lu-TLX250 for non-central nervous system disease; Note: If the investigator feels that the patient is continuing to receive some clinical benefit from standard-of-care (SOC) therapy, the patient may continue SOC therapy up until 2 weeks prior to dosing with 177Lu-TLX250.
* have known brain metastases, unless these have been treated and stabilized for at least 4 weeks prior to the first administration of 177Lu-TLX250; Note: Participants with a history of brain metastases must have either a head CT with contrast-or brain MRI performed at Screening to document stable disease prior to the first administration of 177LuTLX250.
* Have experienced any major trauma including major surgery (such as abdominal/ cardiac/thoracic surgery) within 3 weeks of administration of the first administration of 177LuTLX250;
* be pregnant or intend to become pregnant, breastfeed, or conceive a child during the study period and for at least 42 days after last administration of 89Zr-TLX250 or 6 months after last administration of 177Lu-TLX250, depending on which study drug is administered last to the respective participant;
* Note: Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies (see Appendix 10.4).
* be planning to breastfeed during the study period and for 28 days after last administration of 89ZrTLX250 or 75 days after last administration of 177Lu-TLX250, depending on which study drug is administered last to the respective participant;
* have active and uncontrolled infections requiring systemic therapy or other severe concurrent disease, which, in the opinion of the investigator, would place the participant at undue risk or interfere with the study;
* have a history of concurrent malignancy with a life expectancy of ≤ 2 years or requirement of systemic anti-cancer therapy or requirement of local therapy that would confound study results; however; participants with the following malignancies can be enrolled into the study:

  * basal cell or squamous cell carcinoma of the skin;
  * carcinoma in situ of the cervix, breast or bladder; and/or
  * incidental histologic finding of prostate cancer;
* have a serious, non-healing wound, ulcer, or bone fracture;
* be unable to stay in the scanner bed with the arms resting out of the thoracic and abdominal fields (i.e., arms alongside the body or raised arm position) for the duration of the scan;
* have not had resolution of clinically significant toxic effects of prior systemic cancer therapy, surgery, or radiotherapy to Grade ≤1 (except for laboratory parameters specified above, Grade 2 alopecia, and/or stable Grade 2 sensory neuropathy, according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0;
* have inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis, etc.);
* have a life expectancy shorter than 3 months;
* have bleeding or thrombotic disorders or individuals at risk for severe hemorrhage;
* have experienced any clinically significant bleeding, including hemoptysis or tumor bleeding within 2 weeks prior to the first administration of 177Lu-TLX250;
* has evidence of a serious active or sub-clinical infection or angina pectoris (New York Heart Association \[NYHA\] Class III or IV), significantly prolonged QT interval or other serious illness(es) involving the cardiac, respiratory, central nervous system, renal, hepatic or hematological organ systems, that might impair the ability to complete this study or could interfere with determination of causality of any adverse effects experienced in this study, or which require treatment that could interact with study treatment; or
* have any medical or other condition that in the opinion of the investigator(s) would preclude the individual's participation in a clinical study.

• Results publication: Stillebroer AB, Boerman OC, Desar IM, Boers-Sonderen MJ, van Herpen CM, Langenhuijsen JF, Smith-Jones PM, Oosterwijk E, Oyen WJ, Mulders PF. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol. 2013 Sep;64(3):478-85. doi: 10.1016/j.eururo.2012.08.024. Epub 2012 Aug 21. PMID 22980441
• Results publication: Muselaers CH, Boers-Sonderen MJ, van Oostenbrugge TJ, Boerman OC, Desar IM, Stillebroer AB, Mulder SF, van Herpen CM, Langenhuijsen JF, Oosterwijk E, Oyen WJ, Mulders PF. Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. Eur Urol. 2016 May;69(5):767-70. doi: 10.1016/j.eururo.2015.11.033. Epub 2015 Dec 23. PMID 26706103

NIH grants: 2025